These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 25660204)

  • 1. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
    Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
    J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells.
    Raja SM; Clubb RJ; Bhattacharyya M; Dimri M; Cheng H; Pan W; Ortega-Cava C; Lakku-Reddi A; Naramura M; Band V; Band H
    Cancer Biol Ther; 2008 Oct; 7(10):1630-40. PubMed ID: 18769124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition.
    Raja SM; Desale SS; Mohapatra B; Luan H; Soni K; Zhang J; Storck MA; Feng D; Bielecki TA; Band V; Cohen SM; Bronich TK; Band H
    Oncotarget; 2016 Mar; 7(9):10522-35. PubMed ID: 26859680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
    Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
    Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
    Modi S; Stopeck A; Linden H; Solit D; Chandarlapaty S; Rosen N; D'Andrea G; Dickler M; Moynahan ME; Sugarman S; Ma W; Patil S; Norton L; Hannah AL; Hudis C
    Clin Cancer Res; 2011 Aug; 17(15):5132-9. PubMed ID: 21558407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
    Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB
    Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
    Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
    Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
    Leow CC; Chesebrough J; Coffman KT; Fazenbaker CA; Gooya J; Weng D; Coats S; Jackson D; Jallal B; Chang Y
    Mol Cancer Ther; 2009 Aug; 8(8):2131-41. PubMed ID: 19671750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.
    Rodrigues LM; Chung YL; Al Saffar NM; Sharp SY; Jackson LE; Banerji U; Stubbs M; Leach MO; Griffiths JR; Workman P
    BMC Res Notes; 2012 May; 5():250. PubMed ID: 22621282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.
    Saturno G; Valenti M; De Haven Brandon A; Thomas GV; Eccles S; Clarke PA; Workman P
    Oncotarget; 2013 Aug; 4(8):1185-98. PubMed ID: 23852390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
    Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
    Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
    Weber H; Valbuena JR; Barbhuiya MA; Stein S; Kunkel H; García P; Bizama C; Riquelme I; Espinoza JA; Kurtz SE; Tyner JW; Calderon JF; Corvalán AH; Grez M; Pandey A; Leal-Rojas P; Roa JC
    Oncotarget; 2017 Apr; 8(16):26169-26184. PubMed ID: 28412732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
    Roforth MM; Tan C
    Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model.
    Xu Y; Zhu Q; Chen D; Shen Z; Wang W; Ning G; Zhu Y
    Tumour Biol; 2015 Jul; 36(7):5103-8. PubMed ID: 25682284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
    Modi S; Stopeck AT; Gordon MS; Mendelson D; Solit DB; Bagatell R; Ma W; Wheler J; Rosen N; Norton L; Cropp GF; Johnson RG; Hannah AL; Hudis CA
    J Clin Oncol; 2007 Dec; 25(34):5410-7. PubMed ID: 18048823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer.
    Zhang J; Liu S; Li Q; Shi Y; Wu Y; Liu F; Wang S; Zaky MY; Yousuf W; Sun Q; Guo D; Wang T; Zhang Y; Wang Y; Li M; Liu H
    Cell Death Differ; 2020 Sep; 27(9):2710-2725. PubMed ID: 32327714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells.
    Castagnola P; Bellese G; Birocchi F; Gagliani MC; Tacchetti C; Cortese K
    Oncotarget; 2016 Dec; 7(51):85411-85429. PubMed ID: 27863425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG.
    Wang S; Wang X; Du Z; Liu Y; Huang D; Zheng K; Liu K; Zhang Y; Zhong X; Wang Y
    Biochem Biophys Res Commun; 2014 Jul; 450(1):73-80. PubMed ID: 24879994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.